Abbott Laboratories fired 200 sales representatives preparing to market Vicodin CR (Continued Revenue) after the company stopped plans to introduce the drug this year, people familiar with the matter said.
The drugmaker said in October that the drug, an extended release form of Vicodin, failed to gain U.S. Food and Drug Administration approval. The company hasn’t released details of the so-called complete response letter from the FDA.
More at Bloomberg
The drugmaker said in October that the drug, an extended release form of Vicodin, failed to gain U.S. Food and Drug Administration approval. The company hasn’t released details of the so-called complete response letter from the FDA.
More at Bloomberg
No comments:
Post a Comment